世界の分子細胞遺伝学市場は、2023年に31億ドルの価値があると推定され、2023年から2028年にかけて9.9%のCAGRで成長し、2028年には49億ドルに達すると予測されます。このレポートは市場の業界動向分析で構成されており、業界動向、価格分析、特許分析、会議およびウェビナー資料、主要な利害関係者、および市場における購買行動が含まれています。
目次
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 27)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION
1.3.2 GEOGRAPHIC SCOPE
1.3.3 YEARS CONSIDERED
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 33)
2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
FIGURE 1 MOLECULAR CYTOGENETICS MARKET: RESEARCH DESIGN METHODOLOGY
2.2.1 SECONDARY DATA
2.2.1.1 Key data from secondary sources
2.2.2 PRIMARY DATA
2.2.2.1 Primary sources
2.2.2.2 Key data from primary sources
2.2.2.3 Key industry insights
2.2.2.4 Breakdown of primary interviews
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.3 MARKET SIZE ESTIMATION
2.3.1 BOTTOM-UP APPROACH
2.3.1.1 Approach 1: Company revenue estimation approach
FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
2.3.1.2 Approach 2: Presentations of companies and primary interviews
2.3.1.3 Growth forecast
2.3.1.4 CAGR projections
FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.3.2 TOP-DOWN APPROACH
FIGURE 6 MARKET: TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN & DATA TRIANGULATION
FIGURE 7 DATA TRIANGULATION METHODOLOGY
2.5 MARKET SHARE ANALYSIS
2.6 STUDY ASSUMPTIONS
2.7 RISK ASSESSMENT
2.8 GROWTH RATE ASSUMPTIONS
2.9 RECESSION IMPACT
3 EXECUTIVE SUMMARY (Page No. - 47)
FIGURE 8 MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION)
FIGURE 9 MOLECULAR CYTOGENETICS INDUSTRY, BY TECHNIQUE, 2023 VS. 2028 (USD MILLION)
FIGURE 10 MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
FIGURE 11 MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
FIGURE 12 MARKET, BY REGION, 2023 VS. 2028 (USD MILLION)
4 PREMIUM INSIGHTS (Page No. - 51)
4.1 MOLECULAR CYTOGENETICS MARKET OVERVIEW
FIGURE 13 RISING PREVALENCE OF CANCER AND GENETIC DISORDERS TO DRIVE MARKET
4.2 MOLECULAR CYTOGENETICS INDUSTRY, BY PRODUCT & SERVICE, 2023 VS. 2028
FIGURE 14 KITS & REAGENTS TO CONTINUE TO DOMINATE MARKET IN 2028
4.3 MARKET, BY TECHNIQUE, 2023 VS. 2028
FIGURE 15 COMPARATIVE GENOMIC HYBRIDIZATION TO CONTINUE TO DOMINATE MARKET IN 2028
4.4 MARKET, BY APPLICATION, 2023 VS. 2028
FIGURE 16 CANCER WILL CONTINUE TO DOMINATE MOLECULAR CYTOGENETICS MARKET IN 2028
4.5 MARKET, BY END USER, 2023 VS. 2028
FIGURE 17 CLINICAL & RESEARCH LABORATORIES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
4.6 MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 18 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN MARKET DURING FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 55)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 19 MOLECULAR CYTOGENETICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 MARKET DRIVERS
5.2.1.1 Increasing incidence of cancer and genetic disorders
TABLE 1 PREVALENCE OF GENETIC DISORDERS (2021)
TABLE 2 ESTIMATED NUMBER OF NEW CANCER CASES GLOBALLY, BY TYPE OF CANCER, 2020 VS. 2025
TABLE 3 GLOBAL CANCER INCIDENCE, BY REGION, 2020 VS. 2025
5.2.1.2 Growing focus on targeted cancer treatment
5.2.1.3 Increasing aging population and subsequent rise in prevalence of chronic diseases
5.2.1.4 Increasing penetration of molecular cytogenetics in clinical pathological testing
5.2.2 MARKET RESTRAINTS
5.2.2.1 High cost of advanced instruments
5.2.2.2 Unfavorable reimbursement scenario
5.2.3 MARKET OPPORTUNITIES
5.2.3.1 Untapped emerging markets
5.2.4 MARKET CHALLENGES
5.2.4.1 Transition from FISH to array-based techniques
5.3 PRICING ANALYSIS
5.3.1 PRICING MODEL ANALYSIS
TABLE 4 INDICATIVE PRICING ANALYSIS FOR MOLECULAR CYTOGENETIC PRODUCTS
5.3.2 AVERAGE SELLING PRICE OF MOLECULAR CYTOGENETIC PRODUCTS, BY KEY PLAYER
TABLE 5 AVERAGE SELLING PRICE OF MOLECULAR CYTOGENETIC PRODUCTS
5.4 PATENT ANALYSIS
5.4.1 PATENT ANALYSIS OF MOLECULAR CYTOGENETIC PRODUCTS (JANUARY 2013-DECEMBER 2022)
5.4.2 MOLECULAR CYTOGENETICS INDUSTRY: LIST OF MAJOR PATENTS
5.5 TRADE ANALYSIS
5.5.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
5.5.1.1 Import data for diagnostic and laboratory reagents, by country, 2018-2022 (USD million)
5.5.1.2 Export data for diagnostic and laboratory reagents, by country, 2018-2022 (USD million)
5.6 VALUE CHAIN ANALYSIS
FIGURE 20 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
5.7 SUPPLY CHAIN ANALYSIS
FIGURE 21 MARKET: SUPPLY CHAIN ANALYSIS
5.8 ECOSYSTEM ANALYSIS
FIGURE 22 MARKET: ECOSYSTEM ANALYSIS
5.8.1 ROLE IN ECOSYSTEM
TABLE 6 MARKET: ECOSYSTEM ROLE
5.9 PORTER’S FIVE FORCES ANALYSIS
TABLE 7 MARKET: PORTER’S FIVE FORCES ANALYSIS
5.9.1 THREAT OF NEW ENTRANTS
5.9.2 THREAT OF SUBSTITUTES
5.9.3 BARGAINING POWER OF BUYERS
5.9.4 BARGAINING POWER OF SUPPLIERS
5.9.5 INTENSITY OF COMPETITIVE RIVALRY
5.10 PESTLE ANALYSIS
5.11 REGULATORY ANALYSIS
TABLE 8 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 9 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 10 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 11 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.11.1 NORTH AMERICA
5.11.1.1 US
5.11.1.2 Canada
5.11.2 EUROPE
TABLE 12 EUROPE: CLASSIFICATION OF DEVICES
5.11.3 ASIA PACIFIC
5.11.3.1 China
5.11.3.2 Japan
TABLE 13 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.11.3.3 India
5.11.4 LATIN AMERICA
5.11.4.1 Brazil
5.11.4.2 Mexico
5.11.5 MIDDLE EAST
5.11.6 AFRICA
5.12 KEY CONFERENCES & EVENTS IN 2022-2023
TABLE 14 MOLECULAR DIAGNOSTICS MARKET: DETAILED LIST OF CONFERENCES & EVENTS
5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
FIGURE 23 REVENUE SHIFT AND REVENUE POCKETS FOR MARKET
5.14 KEY STAKEHOLDERS & BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR MOLECULAR CYTOGENETIC PRODUCTS
TABLE 15 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR MOLECULAR CYTOGENETIC PRODUCTS (%)
5.14.2 BUYING CRITERIA
FIGURE 25 KEY BUYING CRITERIA FOR MOLECULAR CYTOGENETIC END USERS
TABLE 16 KEY BUYING CRITERIA
5.15 CASE STUDY ANALYSIS
5.15.1 CASE STUDY: CYTOGENETIC ANALYSIS OF WISKOTT-ALDRICH SYNDROME
6 MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE (Page No. - 81)
6.1 INTRODUCTION
TABLE 17 MOLECULAR CYTOGENETICS INDUSTRY, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
6.2 KITS & REAGENTS
TABLE 18 MARKET FOR KITS & REAGENTS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 19 MARKET FOR KITS & REAGENTS, BY REGION, 2021-2028 (USD MILLION)
6.2.1 TESTING KITS
6.2.1.1 Growing advancements in test kits to support market growth
TABLE 20 MARKET FOR TESTING KITS, BY REGION, 2021-2028 (USD MILLION)
6.2.2 PROBES
6.2.2.1 Increased usage of probes for in situ hybridization to propel market
TABLE 21 MARKET FOR PROBES, BY REGION, 2021-2028 (USD MILLION)
6.2.3 FLUORESCENT AFFINITY REAGENTS
6.2.3.1 Development of novel cytogenetic reagents to drive growth
TABLE 22 MARKET FOR FLUORESCENT AFFINITY REAGENTS, BY REGION, 2021-2028 (USD MILLION)
6.2.4 OTHER KITS & REAGENTS
TABLE 23 MARKET FOR OTHER KITS & REAGENTS, BY REGION, 2021-2028 (USD MILLION)
6.3 INSTRUMENTS
6.3.1 INCREASING USAGE OF INSTRUMENTS IN DRUG DISCOVERY TO DRIVE MARKET
TABLE 24 MARKET FOR INSTRUMENTS, BY REGION, 2021-2028 (USD MILLION)
6.4 CONSUMABLES
6.4.1 INCREASING AWARENESS ABOUT EARLY-STAGE CANCER DIAGNOSIS TO DRIVE MARKET
TABLE 25 MARKET FOR CONSUMABLES, BY REGION, 2021-2028 (USD MILLION)
6.5 SOFTWARE & SERVICES
6.5.1 GROWING NEED FOR SOFTWARE SOLUTIONS FOR HIGH CONTENT SCREENING TO PROPEL MARKET
TABLE 26 MARKET FOR SOFTWARE & SERVICES, BY REGION, 2021-2028 (USD MILLION)
7 MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE (Page No. - 91)
7.1 INTRODUCTION
TABLE 27 MOLECULAR CYTOGENETICS INDUSTRY, BY TECHNIQUE, 2021-2028 (USD MILLION)
7.2 COMPARATIVE GENOMIC HYBRIDIZATION
TABLE 28 MARKET FOR COMPARATIVE GENOMIC HYBRIDIZATION, BY TYPE, 2021-2028 (USD MILLION)
TABLE 29 MARKET FOR COMPARATIVE GENOMIC HYBRIDIZATION, BY REGION, 2021-2028 (USD MILLION)
7.2.1 ARRAY-BASED COMPARATIVE GENOMIC HYBRIDIZATION
7.2.1.1 Rising prevalence of human genetic disorders to support market growth
TABLE 30 MARKET FOR ARRAY-BASED COMPARATIVE GENOMIC HYBRIDIZATION, BY REGION, 2021-2028 (USD MILLION)
7.2.2 STANDARD COMPARATIVE GENOMIC HYBRIDIZATION
7.2.2.1 Increased focus on cancer research to drive growth
TABLE 31 MARKET FOR STANDARD COMPARATIVE GENOMIC HYBRIDIZATION, BY REGION, 2021-2028 (USD MILLION)
7.3 FLUORESCENCE IN SITU HYBRIDIZATION
7.3.1 ADVANCES IN FLUORESCENCE MICROSCOPY TO BOOST MARKET
TABLE 32 MARKET FOR FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2021-2028 (USD MILLION)
7.4 CHROMOGENIC IN SITU HYBRIDIZATION
7.4.1 COST-EFFECTIVENESS OVER FLUORESCENT IN SITU HYBRIDIZATION FISH TO SUPPORT ADOPTION
TABLE 33 MARKET FOR CHROMOGENIC IN SITU HYBRIDIZATION, BY REGION, 2021-2028 (USD MILLION)
7.5 OTHER TECHNIQUES
TABLE 34 MARKET FOR OTHER TECHNIQUES, BY REGION, 2021-2028 (USD MILLION)
8 MOLECULAR CYTOGENETICS MARKET, BY APPLICATION (Page No. - 99)
8.1 INTRODUCTION
TABLE 35 MOLECULAR CYTOGENETICS INDUSTRY, BY APPLICATION, 2021-2028 (USD MILLION)
8.2 GENETIC DISORDERS
8.2.1 INCREASING EFFORTS TO STUDY GENETIC ACTIVITIES TO SUPPORT MARKET GROWTH
TABLE 36 MARKET FOR GENETIC DISORDERS, BY REGION, 2021-2028 (USD MILLION)
8.3 CANCER
8.3.1 STRATEGIC DEVELOPMENTS IN CANCER RESEARCH TO DRIVE MARKET GROWTH
TABLE 37 MARKET FOR CANCER, BY REGION, 2021-2028 (USD MILLION)
8.4 PERSONALIZED MEDICINE
8.4.1 INITIATIVES BY MARKET PLAYERS FOR PERSONALIZED MEDICINE TO SUPPORT MARKET GROWTH
TABLE 38 MARKET FOR PERSONALIZED MEDICINE, BY REGION, 2021-2028 (USD MILLION)
8.5 OTHER APPLICATIONS
TABLE 39 MARKET FOR OTHER APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)
9 MOLECULAR CYTOGENETICS MARKET, BY END USER (Page No. - 105)
9.1 INTRODUCTION
TABLE 40 MOLECULAR CYTOGENETICS INDUSTRY, BY END USER, 2021-2028 (USD MILLION)
9.2 CLINICAL & RESEARCH LABORATORIES
9.2.1 GROWING RESEARCH INTENSITY TO DRIVE USAGE OF MOLECULAR CYTOGENETIC PRODUCTS
TABLE 41 MARKET FOR CLINICAL & RESEARCH INSTITUTES, BY REGION, 2021-2028 (USD MILLION)
9.3 ACADEMIC RESEARCH INSTITUTES
9.3.1 INCREASE IN RESEARCH FUNDING FOR LIFE SCIENCE PROJECTS TO DRIVE MARKET
TABLE 42 MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2021-2028 (USD MILLION)
9.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
9.4.1 GROWING IMPORTANCE OF MOLECULAR CYTOGENETICS FOR DRUG DISCOVERY TO SUPPORT MARKET GROWTH
TABLE 43 MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021-2028 (USD MILLION)
9.5 OTHER END USERS
TABLE 44 MARKET FOR OTHER END USERS, BY REGION, 2021-2028 (USD MILLION)
10 MOLECULAR CYTOGENETICS MARKET, BY REGION (Page No. - 111)
10.1 INTRODUCTION
TABLE 45 MOLECULAR CYTOGENETICS INDUSTRY, BY REGION, 2021-2028 (USD MILLION)
10.2 NORTH AMERICA
TABLE 46 LIST OF RELATED CONFERENCES HELD IN NORTH AMERICA
FIGURE 26 NORTH AMERICA: MOLECULAR CYTOGENETICS MARKET SNAPSHOT
TABLE 47 NORTH AMERICA: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 48 NORTH AMERICA: MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 49 NORTH AMERICA: MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION)
TABLE 50 NORTH AMERICA: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 51 NORTH AMERICA: MARKET, BY END USER, 2021-2028 (USD MILLION)
10.2.1 NORTH AMERICA: RECESSION IMPACT
10.2.2 US
10.2.2.1 US to dominate North American molecular cytogenetics market
TABLE 52 US: MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 53 US: MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION)
TABLE 54 US: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 55 US: MARKET, BY END USER, 2021-2028 (USD MILLION)
10.2.3 CANADA
10.2.3.1 Rising prevalence of cancer to drive market
TABLE 56 CANADA: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 57 CANADA: MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION)
TABLE 58 CANADA: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 59 CANADA: MARKET, BY END USER, 2021-2028 (USD MILLION)
10.3 EUROPE
FIGURE 27 EUROPE: CANCER INCIDENCE & MORTALITY, 2012-2035
TABLE 60 EUROPE: MOLECULAR CYTOGENETICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 61 EUROPE: MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 62 EUROPE: MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION)
TABLE 63 EUROPE: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 64 EUROPE: MARKET, BY END USER, 2021-2028 (USD MILLION)
10.3.1 EUROPE: RECESSION IMPACT
10.3.2 GERMANY
10.3.2.1 Increasing healthcare expenditure with favorable government policies to propel market
TABLE 65 GERMANY: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 66 GERMANY: MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION)
TABLE 67 GERMANY: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 68 GERMANY: MARKET, BY END USER, 2021-2028 (USD MILLION)
10.3.3 UK
10.3.3.1 Availability of government funding and strategic collaborations to boost market
TABLE 69 UK: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 70 UK: MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION)
TABLE 71 UK: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 72 UK: MARKET, BY END USER, 2021-2028 (USD MILLION)
10.3.4 FRANCE
10.3.4.1 Increasing government investments to boost growth of French molecular cytogenetics market
TABLE 73 FRANCE: MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 74 FRANCE: MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION)
TABLE 75 FRANCE: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 76 FRANCE: MARKET, BY END USER, 2021-2028 (USD MILLION)
10.3.5 ITALY
10.3.5.1 Favorable funding scenario to drive adoption of molecular cytogenetics
TABLE 77 ITALY: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 78 ITALY: MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION)
TABLE 79 ITALY: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 80 ITALY: MARKET, BY END USER, 2021-2028 (USD MILLION)
10.3.6 SPAIN
10.3.6.1 Growing demand for genetic testing to create major growth opportunities for market players
TABLE 81 SPAIN: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 82 SPAIN: MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION)
TABLE 83 SPAIN: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 84 SPAIN: MARKET, BY END USER, 2021-2028 (USD MILLION)
10.3.7 REST OF EUROPE
TABLE 85 REST OF EUROPE: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 86 REST OF EUROPE: MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION)
TABLE 87 REST OF EUROPE: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 88 REST OF EUROPE: MARKET, BY END USER, 2021-2028 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 28 ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET SNAPSHOT
TABLE 89 ASIA PACIFIC: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 90 ASIA PACIFIC: MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 91 ASIA PACIFIC: MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION)
TABLE 92 ASIA PACIFIC: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 93 ASIA PACIFIC: MARKET, BY END USER, 2021-2028 (USD MILLION)
10.4.1 ASIA PACIFIC: RECESSION IMPACT
10.4.2 CHINA
10.4.2.1 Increased cancer cases to propel market
TABLE 94 CHINA: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
TABLE 95 CHINA: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 96 CHINA: MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION)
TABLE 97 CHINA: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 98 CHINA: MARKET, BY END USER, 2021-2028 (USD MILLION)
10.4.3 JAPAN
10.4.3.1 Universal health reimbursement policy to support market growth
TABLE 99 JAPAN: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 100 JAPAN: MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION)
TABLE 101 JAPAN: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 102 JAPAN: MARKET, BY END USER, 2021-2028 (USD MILLION)
10.4.4 INDIA
10.4.4.1 Increasing adoption of technology to support market growth
TABLE 103 INDIA: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 104 INDIA: MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION)
TABLE 105 INDIA: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 106 INDIA: MARKET, BY END USER, 2021-2028 (USD MILLION)
10.4.5 REST OF ASIA PACIFIC
TABLE 107 REST OF ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 108 REST OF ASIA PACIFIC: MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION)
TABLE 109 REST OF ASIA PACIFIC: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 110 REST OF ASIA PACIFIC: MARKET, BY END USER, 2021-2028 (USD MILLION)
10.5 LATIN AMERICA
10.5.1 EXPANSIONS OF KEY PLAYERS IN LATIN AMERICAN REGION TO BOOST MARKET
TABLE 111 LATIN AMERICA: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 112 LATIN AMERICA: MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION)
TABLE 113 LATIN AMERICA: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 114 LATIN AMERICA: MARKET, BY END USER, 2021-2028 (USD MILLION)
10.5.2 LATIN AMERICA: RECESSION IMPACT
10.6 MIDDLE EAST & AFRICA
10.6.1 ADVANCEMENTS IN DIAGNOSTIC TECHNOLOGIES AND INCREASED HEALTHCARE INVESTMENT TO PROPEL MARKET
TABLE 115 MIDDLE EAST & AFRICA: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
TABLE 116 MIDDLE EAST & AFRICA: MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION)
TABLE 117 MIDDLE EAST & AFRICA: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 118 MIDDLE EAST & AFRICA: MARKET, BY END USER, 2021-2028 (USD MILLION)
10.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
11 COMPETITIVE LANDSCAPE (Page No. - 160)
11.1 OVERVIEW
11.2 STRATEGIES OF KEY PLAYERS
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN MOLECULAR CYTOGENETICS MARKET
TABLE 119 OVERVIEW OF STRATEGIES DEPLOYED BY KEY MOLECULAR CYTOGENETICS MANUFACTURING COMPANIES
11.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
FIGURE 29 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN MOLECULAR CYTOGENETICS INDUSTRY
11.4 MARKET SHARE ANALYSIS
FIGURE 30 MOLECULAR CYTOGENETICS INDUSTRY SHARE, BY KEY PLAYER, 2022
TABLE 120 MOLECULAR CYTOGENETICS INDUSTRY: DEGREE OF COMPETITION
11.5 COMPANY EVALUATION MATRIX
11.5.1 LIST OF EVALUATED VENDORS
11.5.2 STARS
11.5.3 EMERGING LEADERS
11.5.4 PERVASIVE PLAYERS
11.5.5 PARTICIPANTS
FIGURE 31 MOLECULAR CYTOGENETICS INDUSTRY: COMPANY EVALUATION MATRIX, 2022
11.5.6 COMPANY FOOTPRINT ANALYSIS
TABLE 121 COMPANY TYPE FOOTPRINT
TABLE 122 COMPANY REGIONAL FOOTPRINT
11.6 STARTUP/SME EVALUATION MATRIX
11.6.1 PROGRESSIVE COMPANIES
11.6.2 RESPONSIVE COMPANIES
11.6.3 DYNAMIC COMPANIES
11.6.4 STARTING BLOCKS
FIGURE 32 MOLECULAR CYTOGENETICS INDUSTRY: STARTUP/SME EVALUATION MATRIX, 2022
11.6.5 COMPETITIVE BENCHMARKING
FIGURE 33 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS OF TOP PLAYERS IN MOLECULAR CYTOGENETICS INDUSTRY
TABLE 123 MOLECULAR CYTOGENETICS INDUSTRY: COMPETITIVE BENCHMARKING OF KEY PLAYERS
11.7 COMPETITIVE SCENARIO & TRENDS
11.7.1 PRODUCT LAUNCHES
TABLE 124 KEY PRODUCT LAUNCHES & APPROVALS (JANUARY 2020-NOVEMBER 2023)
11.7.2 DEALS
TABLE 125 KEY DEALS (JANUARY 2020-NOVEMBER 2023)
11.7.3 OTHER DEVELOPMENTS
TABLE 126 OTHER DEVELOPMENTS (JANUARY 2020-NOVEMBER 2023)
12 COMPANY PROFILES (Page No. - 174)
(Business Overview, Products Offered, Recent Developments, MnM View Right to win, Strategic choices made, Weaknesses and competitive threats) *
12.1 KEY PLAYERS
12.1.1 F. HOFFMANN-LA ROCHE LTD.
TABLE 127 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
FIGURE 34 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)
12.1.2 DANAHER CORPORATION
TABLE 128 DANAHER CORPORATION: COMPANY OVERVIEW
FIGURE 35 DANAHER CORPORATION: COMPANY SNAPSHOT (2022)
12.1.3 AGILENT TECHNOLOGIES, INC.
TABLE 129 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
FIGURE 36 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2022)
12.1.4 ABBOTT LABORATORIES
TABLE 130 ABBOTT LABORATORIES: COMPANY OVERVIEW
FIGURE 37 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2022)
12.1.5 THERMO FISHER SCIENTIFIC, INC.
TABLE 131 THERMO FISHER SCIENTIFIC, INC.: COMPANY OVERVIEW
FIGURE 38 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2022)
12.1.6 ILLUMINA INC.
TABLE 132 ILLUMINA INC.: COMPANY OVERVIEW
FIGURE 39 ILLUMINA INC.: COMPANY SNAPSHOT (2022)
12.1.7 REVVITY
TABLE 133 REVVITY: COMPANY OVERVIEW
FIGURE 40 REVVITY: COMPANY SNAPSHOT (2022)
12.1.8 PACIFIC BIOSCIENCES
TABLE 134 PACIFIC BIOSCIENCES: COMPANY OVERVIEW
FIGURE 41 PACIFIC BIOSCIENCES: COMPANY SNAPSHOT (2022)
12.1.9 BIO-RAD LABORATORIES, INC.
TABLE 135 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
FIGURE 42 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022)
12.1.10 BIO-TECHNE CORPORATION
TABLE 136 BIO-TECHNE CORPORATION: COMPANY OVERVIEW
FIGURE 43 BIO-TECHNE CORPORATION: COMPANY SNAPSHOT (2022)
12.1.11 GENEDX
TABLE 137 GENEDX: COMPANY OVERVIEW
FIGURE 44 GENEDX: COMPANY SNAPSHOT (2022)
12.1.12 ONCOCYTE CORPORATION
TABLE 138 ONCOCYTE CORPORATION: COMPANY OVERVIEW
FIGURE 45 ONCOCYTE CORPORATION: COMPANY SNAPSHOT (2022)
12.1.13 BIOVIEW
TABLE 139 BIOVIEW: COMPANY OVERVIEW
12.2 OTHER PLAYERS
12.2.1 OXFORD GENE TECHNOLOGY IP LIMITED (PART OF SYSMEX)
12.2.2 APPLIED SPECTRAL IMAGING, INC.
12.2.3 CYTOTEST INC.
12.2.4 KROMATID, INC.
12.2.5 GENIAL GENETIC SOLUTIONS LTD.
12.2.6 CYTOGNOMIX, INC.
12.2.7 METASYSTEMS
12.2.8 SCIGENE
12.2.9 BIOMODAL
12.2.10 BIOCARE MEDICAL
12.2.11 BIODOT
12.2.12 ONCODNA
*Details on Business Overview, Products Offered, Recent Developments, MnM View, Right to win, Strategic choices made, Weaknesses and competitive threats might not be captured in case of unlisted companies.
13 APPENDIX (Page No. - 233)
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
